How a Kinase Inhibitor Withstands Gatekeeper Residue Mutations

Area of Science:

• Biochemistry
• Computational Biology
• Pharmacology

Background:

• Kinase gatekeeper mutations confer resistance to cancer therapies.
• Developing mutation-resistant kinase inhibitors is vital for effective cancer treatment.

Purpose of the Study:

• To investigate the molecular mechanisms behind resistance to cSrc kinase inhibitors caused by the T338M gatekeeper mutation.
• To compare the efficacy of type I (Dasatinib) and type II (RL45) inhibitors against this mutation using atomistic simulations.

Main Methods:

• Utilized enhanced sampling techniques, specifically free energy perturbation with replica exchange solute tempering (FEP/REST).
• Performed atomistic simulations to analyze thermodynamic and structural properties of inhibitor-kinase interactions.

Main Results:

• Dasatinib showed favorable binding to wild-type cSrc but unfavorable binding to the T338M mutant.
• RL45 demonstrated favorable binding to both wild-type and T338M mutant kinases.
• Dasatinib's failure is attributed to lost hydrogen bonding and steric hindrance from an inflexible ring.
• RL45's success is linked to phenyl ring flexibility and favorable electrostatic interactions with phenylalanine.

Conclusions:

• RL45 effectively overcomes cSrc T338M gatekeeper mutations due to its structural flexibility.
• Enhanced sampling simulations provide accurate insights into drug resistance mechanisms.
• This study aids in designing next-generation, mutation-resistant kinase inhibitors.